Top

International Journal of Clinical Oncology

Published in:

01-06-2020 | Hepatocellular Carcinoma | Original Article

RETRACTED ARTICLE: Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma

Authors: Chuantao Zhang, Jianxiang Liu, Zhiyi Han, Xiang Cui, Deti Peng, Yufeng Xing

Published in: International Journal of Clinical Oncology | Issue 6/2020

Abstract

Background

Increase of the Ca²⁺-activated chloride channel TMEM16A is contribute to tumorigenesis. However, the expression level of TMEM16A and its underlying molecular mechanism for TMEM16Apromotingliver carcinogenesis is remains unknown.

Methods

In the present study, the expression of TMEM16A in hepatocellular carcinoma (HCC) tissues were measured by quantitative reverse-transcription polymerase chain reaction (qRT-PCR), Western blot and immunohistochemical. Cell proliferation was detected using CCK-8, EdU staining and colony formation methods. Flow cytometry was carried out for detecting cell cycle distribution and apoptosis rate. Migration and invasion abilities were analyzed using transwell and wound healing assay. Western blot method was performed to analyze protein expression.

Results

Here, we found TMEM16A was significantly increased in HCC tissues, and a higher TMEM16A expression levels were detected in larger tumor size, higher tumor grade, with distant metastasis and poor differentiation. Moreover, overexpression of TMEM16A promoted HCC growth, migration and invasion, and suppressed apoptosis in vitro and in vivo. Knockdown of TMEM16A inhibited HCC growth, migration and invasion, and induced apoptosis in vitro and in vivo. Furthermore, TMEM16A regulated PI3K/AKT-MAKP signaling pathway.

Conclusion

Our data indicate that TMEM16A may represent a novel biomarker of HCC and may be a potential therapeutic target for diagnosis and therapy.

Sia D, Villanueva A, Friedman SL et al (2017) Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 152(4):745–761. https://doi.org/10.1053/j.gastro.2016.11.048CrossRefPubMed

Wanqing C, Rongshou Z, Baade DP et al (2016) Cancer statistics in China, 2015. CA A Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338CrossRef

Kudo M, Trevisani F, Abou-Alfa GK et al (2016) Hepatocellular carcinoma: therapeutic guidelines and medical treatment. Liver Cancer 6(1):16–26. https://doi.org/10.1159/000449343CrossRefPubMedPubMedCentral

Li J, Zhang Q, Fan X et al (2017) The long noncoding RNA TUG1 acts as a competing endogenous RNA to regulate the Hedgehog pathway by targeting miR-132 in hepatocellular carcinoma. Oncotarget 8(39):65932–65945. https://doi.org/10.18632/oncotarget.19582CrossRefPubMedPubMedCentral

Gokcan H, Savas N, Oztuna D et al (2015) Predictors of survival in hepatocellular carcinoma patients. Ann Transpl 20:596–603. https://doi.org/10.12659/aot.894878CrossRef

Caputo A, Caci E, Ferrera L et al (2008) TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science (New York, NY) 322(5901):590–594. https://doi.org/10.1126/science.1163518CrossRef

Huang F, Rock JR, Harfe BD et al (2009) Studies on expression and function of the TMEM16A calcium-activated chloride channel. Proc Natl Acad Sci USA 106(50):21413–21418. https://doi.org/10.1073/pnas.0911935106CrossRefPubMedPubMedCentral

Rodriguez E, Rao PH, Ladanyi M et al (1990) 11p13-15 is a specific region of chromosomal rearrangement in gastric and esophageal adenocarcinomas. Can Res 50(19):6410–6416

Sui Y, Sun M, Wu F et al (2014) Inhibition of TMEM16A expression suppresses growth and invasion in human colorectal cancer cells. PLoS ONE 9(12):e115443. https://doi.org/10.1371/journal.pone.0115443CrossRefPubMedPubMedCentral

10.

Duvvuri U, Shiwarski DJ, Xiao D et al (2012) TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Can Res 72(13):3270–3281. https://doi.org/10.1158/0008-5472.can-12-0475-tCrossRef

11.

Britschgi A, Bill A, Brinkhaus H et al (2013) Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci USA 110(11):E1026–1034. https://doi.org/10.1073/pnas.1217072110CrossRefPubMedPubMedCentral

12.

Liu J, Liu Y, Ren Y et al (2014) Transmembrane protein with unknown function 16A overexpression promotes glioma formation through the nuclear factor-kappaB signaling pathway. Mol Med Rep 9(3):1068–1074. https://doi.org/10.3892/mmr.2014.1888CrossRefPubMed

13.

Sauter DRP, Novak I, Pedersen SF et al (2015) ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC). Pflugers Arch 467(7):1495–1508. https://doi.org/10.1007/s00424-014-1598-8CrossRefPubMed

14.

Deng L, Yang J, Chen H et al (2016) Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma. OncoTargets Therapy 9:325–333. https://doi.org/10.2147/ott.s95985CrossRefPubMedPubMedCentral

15.

Lee YS, Lee JK, Bae Y et al (2016) Suppression of 14–3-3gamma-mediated surface expression of ANO1 inhibits cancer progression of glioblastoma cells. Sci Rep 6:26413. https://doi.org/10.1038/srep26413CrossRefPubMedPubMedCentral

16.

Guan L, Song Y, Gao J et al (2016) Inhibition of calcium-activated chloride channel ANO1 suppresses proliferation and induces apoptosis of epithelium originated cancer cells. Oncotarget 7(48):78619–78630. https://doi.org/10.18632/oncotarget.12524CrossRefPubMedPubMedCentral

17.

Berglund E, Akcakaya P, Berglund D et al (2014) Functional role of the Ca(2)(+)-activated Cl(−) channel DOG1/TMEM16A in gastrointestinal stromal tumor cells. Exp Cell Res 326(2):315–325. https://doi.org/10.1016/j.yexcr.2014.05.003CrossRefPubMed

18.

Mittal S, El-Serag HB (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 47(Suppl):S2–6. https://doi.org/10.1097/MCG.0b013e3182872f29CrossRefPubMedPubMedCentral

19.

Wu H, Wang H, Guan S et al (2017) Cell-specific regulation of proliferation by Ano1/TMEM16A in breast cancer with different ER, PR, and HER2 status. Oncotarget 8(49):84996–85013. https://doi.org/10.18632/oncotarget.18662CrossRefPubMedPubMedCentral

20.

Finegersh A, Kulich S, Guo T et al (2017) DNA methylation regulates TMEM16A/ANO1 expression through multiple CpG islands in head and neck squamous cell carcinoma. Sci Rep 7(1):15173. https://doi.org/10.1038/s41598-017-15634-9CrossRefPubMedPubMedCentral

21.

Huang F, Zhang H, Wu M et al (2012) Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci USA 109(40):16354–16359. https://doi.org/10.1073/pnas.1214596109CrossRefPubMedPubMedCentral

22.

Wang M, Yang H, Zheng LY et al (2012) Downregulation of TMEM16A calcium-activated chloride channel contributes to cerebrovascular remodeling during hypertension by promoting basilar smooth muscle cell proliferation. Circulation 125(5):697–707. https://doi.org/10.1161/circulationaha.111.041806CrossRefPubMed

23.

Oh U, Jung J (2016) Cellular functions of TMEM16/anoctamin. Pflugers Arch 468(3):443–453. https://doi.org/10.1007/s00424-016-1790-0CrossRefPubMedPubMedCentral

24.

Wanitchakool P, Ousingsawat J, Sirianant L et al (2016) Cl(−) channels in apoptosis. Eur Biophys J 45(7):599–610. https://doi.org/10.1007/s00249-016-1140-3CrossRefPubMed

25.

Wang B, Li C, Huai R et al (2015) Overexpression of ANO1/TMEM16A, an arterial Ca2+-activated Cl− channel, contributes to spontaneous hypertension. J Mol Cell Cardiol 82:22–32. https://doi.org/10.1016/j.yjmcc.2015.02.020CrossRefPubMed

26.

Wu H, Guan S, Sun M et al (2015) Ano1/TMEM16A overexpression is associated with good prognosis in PR-positive or HER2-negative breast cancer patients following tamoxifen treatment. PLoS ONE 10(5):e0126128. https://doi.org/10.1371/journal.pone.0126128CrossRefPubMedPubMedCentral

27.

Cao Q, Liu F, Ji K et al (2017) MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res 36:29. https://doi.org/10.1186/s13046-017-0499-zCrossRefPubMedPubMedCentral

28.

Song Y, Gao J, Guan L et al (2018) Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-α signaling. Cell Death Dis 9(6):703. https://doi.org/10.1038/s41419-018-0735-2CrossRefPubMedPubMedCentral

29.

Lee FT, Mountain AJ, Kelly MP et al (7086s) Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 11(19 Pt 2):7080s–7086s. https://doi.org/10.1158/1078-0432.ccr-1004-0019CrossRefPubMed

30.

Almaca J, Tian Y, Aldehni F et al (2009) TMEM16 proteins produce volume-regulated chloride currents that are reduced in mice lacking TMEM16A. J Biol Chem 284(42):28571–28578. https://doi.org/10.1074/jbc.M109.010074CrossRefPubMedPubMedCentral

31.

Maire V, Nemati F, Richardson M et al (2013) Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Can Res 73(2):813–823. https://doi.org/10.1158/0008-5472.can-12-2633CrossRef

32.

Li B, Li J, Xu WW et al (2014) Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway. Oncotarget 5(22):11576–11587CrossRef

Title: RETRACTED ARTICLE: Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma
Authors: Chuantao Zhang
Jianxiang Liu
Zhiyi Han
Xiang Cui
Deti Peng
Yufeng Xing
Publication date: 01-06-2020
Publisher: Springer Singapore
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: International Journal of Clinical Oncology / Issue 6/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01653-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis

Tumor-agnostic precision oncology: striving to prioritize internationalization for the management of cancer patients

Down-regulation of miR-200c associates with poor prognosis of oral squamous cell carcinoma

Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System

Keynote webinar | Spotlight on antibody–drug conjugates in cancer